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Christian Wolfrum,3 and Timo D. M€uller1,2,18,19,*
1Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum M€unchen, Neuherberg, Germany
2German Center for Diabetes Research (DZD), Neuherberg, Germany
3Institute of Food, Nutrition and Health, Department of Health Sciences and Technology (D-HEST), ETH Z€urich, Zurich, Switzerland
4Cardiometabolic Diseases Research Department, Boehringer Ingelheim Pharma GmbH and Co., KG, Biberach/Riss, Germany
5Institute of Diabetes and Regeneration Research, Helmholtz Zentrum M€unchen, 85764 Neuherberg, Germany
6Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, ON M5G 1X5, Canada
7Research Unit Analytical Pathology, Helmholtz Zentrum M€unchen, Neuherberg, Germany
8Institute for Diabetes and Cancer, Helmholtz Diabetes Center, Helmholtz Center Munich, Neuherberg, Germany
9Molecular Metabolic Control, Technical University of Munich, Munich, Germany
10Medizinische Klinik und Poliklinik IV, Klinikum der LMU, M€unchen, Germany
11Department of Molecular Biosciences, The Wenner-Gren Institute, The Arrhenius Laboratories F3, Stockholm University, Stockholm,
Sweden
12Novo Nordisk Research Center Indianapolis, Indianapolis, IN 46241, USA
13Technische Universit€at M€unchen, School of Medicine, Klinikum Rechts der Isar, 81675 M€unchen, Germany
14Department of Pharmacology and Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, OH, USA
15Department of Chemistry, Indiana University, Bloomington, IN 47405, USA
16Helmholtz Zentrum M€unchen, Neuherberg, Germany
17Technische Universit€at M€unchen, M€unchen, Germany
18Department of Pharmacology and Experimental Therapy, Institute of Experimental and Clinical Pharmacology and Toxicology, Eberhard
Karls University Hospitals and Clinics, 72076 T€ubingen, Germany
19Lead contact
*Correspondence: timo.mueller@helmholtz-muenchen.de
https://doi.org/10.1016/j.cmet.2021.01.015SUMMARYUncertainty exists as to whether the glucose-dependent insulinotropic polypeptide receptor (GIPR) should
be activated or inhibited for the treatment of obesity. Gipr was recently demonstrated in hypothalamic
feeding centers, but the physiological relevance of CNS Gipr remains unknown. Here we show that HFD-
fed CNS-Gipr KO mice and humanized (h)GIPR knockin mice with CNS-hGIPR deletion show decreased
body weight and improved glucose metabolism. In DIO mice, acute central and peripheral administration
of acyl-GIP increases cFos neuronal activity in hypothalamic feeding centers, and this coincides with
decreased body weight and food intake and improved glucose handling. Chronic central and peripheral
administration of acyl-GIP lowers body weight and food intake in wild-type mice, but shows blunted/absent
efficacy in CNS-GiprKOmice. Also, the superior metabolic effect of GLP-1/GIP co-agonism relative to GLP-1
is extinguished in CNS-Gipr KO mice. Our data hence establish a key role of CNS Gipr for control of energy
metabolism.INTRODUCTION
The glucose-dependent insulinotropic polypeptide (GIP) regu-
lates blood glucose via its insulinotropic and glucagonotropicCell Metabolism 33, 833–844
This is an open access article undaction on the pancreas (Christensen et al., 2011; Finan et al.,
2016). While the glycemic effects of GIP receptor (GIPR) ago-
nism are solidly confirmed, uncertainty exists as to whether
GIPR should be stimulated or inhibited for the treatment of, April 6, 2021 ª 2021 The Authors. Published by Elsevier Inc. 833
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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OPEN ACCESS Articletype 2 diabetes mellitus (T2DM) and obesity (Holst and Rose-
nkilde, 2020). Global germline Gipr knockout (KO) mice show
lower body weight and preserved insulin sensitivity upon high-
fat diet (HFD) feeding (Miyawaki et al., 2002), and the insulino-
tropic response to GIP is impaired in patients with T2DM (Nauck
et al., 1993). GIP activates lipoprotein lipase (Eckel et al., 1979;
Kim et al., 2007, 2010), stimulates uptake of fatty acids and
glucose (Beck and Max, 1986; Hauner et al., 1988), and pro-
motes lipid synthesis in cultured adipocytes (Hauner et al.,
1988). These data align with studies in humans, in which GIP is
shown to promote lipid storage by increasing adipose tissue
blood flow and triglyceride uptake (Asmar et al., 2017). These
and other data have spurred the development of GIPR antago-
nists for the treatment of T2DM and obesity. Recently, it was
shown that GIPR antagonizing antibodies improve body weight
and glucose control in mice and non-human primates (Killion
et al., 2018) and enhance the anorectic effect of leptin in HFD-
fed mice (Kaneko et al., 2019). In contrast to these data, overex-
pression of Gip improves body weight and glycemia in HFD-fed
mice (Kim et al., 2012). Pigs expressing a dominant-negative
Gipr in the b cells are glucose intolerant and show reduced
glucose stimulation of insulin secretion (Renner et al., 2010).
Optimized GIP analogs decrease body weight in wild-type
(WT) and GLP-1 receptor (GLP-1R) KO mice, but fail to do so
in mice deficient for Gipr (Mroz et al., 2019). Co-administration
of a GLP-1R agonist with a GIPR agonist synergistically de-
creases body weight and fat mass in diet-induced obese (DIO)
mice (Finan et al., 2013). Unimolecular dual-agonists targeting
the receptors for GLP-1 and GIP decrease body weight and
improve glucose handling in animal models of obesity and
T2DM (Coskun et al., 2018; Finan et al., 2013), non-human pri-
mates (Finan et al., 2013), and obese patients with T2DM (Cos-
kun et al., 2018; Finan et al., 2013; Frias et al., 2018). Moreover,
the dual-agonists exhibit greater efficacy relative to GLP-1R ag-
onism alone in preclinical studies (Coskun et al., 2018; Finan
et al., 2013) and clinical trials (Frias et al., 2018). In summary,
there is considerable uncertainty as to how GIPR agonism
versus antagonism improves energy metabolism.
Expression of Gipr was recently demonstrated in cells/neu-
rons of the arcuate (ARC), dorsomedial (DMH), and paraventric-
ular (PVH) nuclei of the hypothalamus, and Gq-DREADD-medi-
ated activation of these neurons/cells decreases food intake in
mice (Adriaenssens et al., 2019). While these data indicate that
Gipr is located on hypothalamic neurons that control feeding
behavior, these Gipr-expressing neurons/cells most likely also
express other factors that affect food intake. Hence, it remains
unclear whether CNS Gipr signaling is of relevance for energy
metabolism control in general and for the metabolic effects of
GIP-based pharmacotherapies specifically.
The aim of our studies is to assess the role of CNS Gipr in the
systemic regulation of body weight, food intake, energy expen-
diture, and glucose metabolism. We show that mice with CNS
deletion of murine (m)Gipr (nestin cre+/ mGiprflx/fl) and also hu-
manized (h)GIPR knockin mice with conditional CNS deletion of
hGIPR (nestin cre+/ hGIPRflx/flx) phenocopy global germlineGipr
KO mice with respect to lower body weight and improved
glucose metabolism upon HFD feeding. The lower body weight
of CNS-mGipr KO mice and of CNS-hGIPR KO mice is accom-
panied by decreased food intake without changes in energy834 Cell Metabolism 33, 833–844, April 6, 2021expenditure. Consistent with localization ofGipr in hypothalamic
nuclei linked to control of appetite (Adriaenssens et al., 2019), we
show that acute central and peripheral administration of fatty
acyl-GIP increases cFOS neuronal activity in key hypothalamic
feeding centers and that this coincides acutely and chronically
with decreased body weight, food intake, and blood glucose.
Chronic central (intracerebroventricular, i.c.v.) and peripheral
(subcutaneous, s.c.) treatment with fatty acyl-GIP improves
bodyweight and food intake in DIOWTmice, but this effect is ab-
sent upon i.c.v. fatty acyl-GIP treatment and blunted upon s.c.
acyl-GIP treatment in CNS-Gipr KO mice. Also, the superior
metabolic effects of unimolecular GLP-1/GIP dual-agonism rela-
tive to treatment with GLP-1 alone are extinguished in CNS-Gipr
KO mice. In summary, our data reveal new roles for CNS Gipr
signaling in control of energy metabolism and indicate that cen-
tral Gipr signaling is essential for the anorectic effect of GIPR ag-
onism and the metabolic benefits of dual GLP-1/GIP agonists.
RESULTS
Mice with CNS-specific deletion of mGipr are protected
from diet-induced obesity and glucose intolerance
To evaluate the role of CNS Gipr signaling for systemic energy
metabolism control, we generated mice in which mGipr is
deleted in the CNS by crossing mGiprflx/flx mice (Ussher et al.,
2018) with mice that express the cre recombinase under control
of the nestin promoter. Consistent with the phenotype of germ-
line global Gipr KO mice (Miyawaki et al., 2002), CNS-mGipr
KO mice showed lower body weight relative to WT control
mice when chronically fed with an HFD (Figure 1A). Consistent
with this, body fat, but not lean tissue mass, was decreased in
CNS-mGipr KO mice (Figures 1B and 1C). CNS-mGipr KO
mice exhibited reduced food intake (Figure 1D) with unchanged
assimilated energy per gram eaten food (Figure 1E) and
increased locomotor activity (Figure 1F) without transcriptional
changes in hypothalamic Npy, Agrp, Pomc, or Cart (Figure 1G).
No changes were observed in total energy expenditure, resting
metabolic rate (Figures 1H and 1I), or expression of genes related
to thermogenesis in brown adipose tissue (BAT) (Figure 1J). Also,
substrate utilization (Figure 1K) and plasma levels of triglycerides
and cholesterol (Figures 1L and 1M) were unchanged. CNS-
mGipr KO mice showed improved glucose tolerance (Figures
1N and 1O) and decreased HbA1c (Figure 1P) without differ-
ences in fasting levels of blood glucose (Figure 1Q), but lower
plasma levels of insulin (Figure 1R) and improved insulin sensi-
tivity approximated by HOMA-IR (Figure 1S). Gene expression
profiling showed a robust (95%) decrease in Gipr mRNA in
the hypothalamus (Figure 1T) of CNS-Gipr KO mice with un-
changed expression in isolated islets (Figure 1U), bone marrow,
or white (WAT) and brown adipose tissue (BAT) (Figures S1A–
S1C). In line with preservation of Gipr expression in the islets
(Figure 1U), we saw no difference in glucose-stimulated insulin
secretion (GSIS) between islets isolated from WT and CNS-
mGipr KO mice (Figure 1V) and preservation of GLP-1 and GIP
to stimulate islet insulin secretion (Figure 1W). Collectively, these
data demonstrate that islet incretin action is not compromised in
the CNS-mGipr KO mice.
Similar to the phenotype of the global germline Gipr KO mice
(Miyawaki et al., 2002), we saw no difference in body weight,
Figure 1. Mice with CNS deletion of murine Gipr are protected from diet-induced obesity and glucose intolerance
(A–E) Body weight (A), body composition at the age of 28 weeks (B and C), food intake (D), and assimilated energy (E) in 42-week-old male C57BL/6J WT and
CNS-Gipr KOmice (N = 7–8mice each group) fed with a high-fat diet (HFD). Food intake and assimilated energy were assessed per cage in double-housedmice.
(F–I) Locomotor activity (N = 7–8 mice each group) (F), hypothalamic expression of genes related to food intake (6–7 mice each group) (G), and total energy
expenditure (H) and resting metabolic rate (I) in 29-week-old male mice (N = 7–8 mice each group).
(J) Expression of genes related to BAT thermogenesis in HFD-fed male mice (N = 8 each genotype).
(K) Respiratory exchange ratio (RER) in 29-week-old male mice (N = 7–8 mice each group).
(L–O) Plasma levels of triglycerides (L) and cholesterol (M) (N = 6–7 each group) and intraperitoneal glucose tolerance (N and O) (N = 6–8 mice each group) in
42-week-old male mice.
(P) HbA1c (N = 18 mice each group; p = 0.0033).
(Q and R) Fasting levels of blood glucose (Q) and insulin (R) as well as HOMA-IR (S) in 42-week-old male mice (N = 7–8 each group).
(T andU) Relative expression ofGipr (corrected to housekeeping gene peptidylprolyl isomerase B;Ppib) in the hypothalamus (N = 8mice each genotype) (T) and in
isolated islets from WT and CNS-Gipr KO mice (N = 3 each group) (U).
(V andW) Glucose-stimulated insulin secretion (GSIS) in isolated islets under conditions of low (2.8mM) and high glucose (16.8 mM) (V) and GSIS of isolated islets
treatedwith or without 10 nMof either acyl-GLP-1 or acyl-GIP (W) (N = 4mice each group). y axis in (W) represents the ratio of secreted insulin stimulated with high
glucose (16.8 mM) to low glucose (2.8 mM).
Data represent means ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001. Longitudinal data (A and N) were analyzed using two-way ANOVAwith time and genotype as
co-variables andBonferroni post hoc analysis for individual time points. Bar graphs (B–G, J–M, andO–W)were analyzed using two-tailed, two-sided t test. Data in
(H) and (I) were analyzed using ANCOVA with body weight as co-variate.
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CNS-mGiprKOmicewere fedwith a standard chowdiet (Figures
S2A–S2E). Further, no differences were seen in either plasma
levels of blood glucose and insulin or in insulin sensitivity approx-
imated by HOMA-IR (Figures S2F–S2H). Also, plasma levels of
GLP-1 were unchanged between WT and CNS-mGipr KO mice
under both baseline conditions and after oral administration of
glucose (Figure S2I). In summary, these data show that CNS-
specific loss of mGipr phenocopies the global germline loss of
Gipr with regard to lower body weight and improved glucose
metabolism under HFD, but not chow-fed conditions.
Humanized GIPR knockin mice with conditional CNS-
specific hGIPR deletion are protected from diet-induced
obesity and glucose intolerance
To further validate the phenotype arising from selective elimina-
tion of the CNS-Gipr, we generated hGIPR knockin mice with
conditional nestin cre-mediated hGIPR deletion in the CNS.
Such CNS-hGIPR KO mice showed decreased mRNA levels of
hGIPR in the hypothalamus, ventral tegmental area (VTA), hippo-
campus, and cortex with unchanged GIPR expression in BAT,
inguinal (iWAT) and epididymal WAT (eWAT), and the liver (Fig-
ure S3A). Consistent with the phenotype of the CNS-specific
mGipr KO mice, the CNS-specific hGIPR KO mice also showed
reducedweight gain over time upon HFD exposure relative to the
humanized control mice (Figure 2A). The lower body weight of
the CNS-specific hGIPR KO mice was paralleled by a decrease
in body fat and lean tissue mass (Figures 2B and 2C) and food
intake (Figure 2D) that is associated with increased expression
ofPomc,Bdnf, andCart in the hypothalamus (Figure 2E). Consis-
tent with the CNS-mGIPR KO mice, the CNS-hGIPR KO mice
also showed no difference in energy expenditure, but trended to-
ward increased physical activity in the dark phase (Figures 2F
and 2G). Consistent with the lower body weight, we also saw
improved glucose metabolism in CNS-specific hGIPR KO
mice, as indicated by enhanced glucose tolerance (Figure 2H)
and decreased fasting levels of glucose and insulin (Figures 2I
and 2J). Fasting plasma levels of total GLP-1 were increased in
CNS-hGIPR KO mice while levels of leptin, triglycerides, and
non-esterified fatty acids (NEFAs) were decreased (Figures 2K–
2N). No difference was observed in plasma levels of GIP and
cholesterol (Figures 2O and 2P), but hepatic lipid accumulation
was decreased in CNS-hGIPR KOmice (Figure 2Q). In summary,
mice with CNS-specific ablation of the murine or human GIP re-
ceptor phenocopy global Gipr KO mice with respect to reduced
weight gain and improved glucose metabolism upon HFD
feeding. Notably, no difference in body weight or blood glucose
was observed between WT nestin cre/ hGIPRflx/flx, nestin
cre+/ hGIPRwt/wt, and nestin cre/ hGIPRwt/wt mice (Figures
S3B and S3C).
Acute central administration of fatty acyl-GIP improves
body weight, food intake, and glycemia in DIO mice
We next assessed the acute metabolic effects of single i.c.v.
administration of a validated long-acting (fatty acylated) GIP
(IUB0271; Figure S1D) in DIO mice (Mroz et al., 2019). Acute
i.c.v. administration of fatty acyl-GIP dose-dependently
decreased body weight relative to vehicle controls (Figure 3A).
We saw reduced food intake in fatty acyl-GIP-treated mice (Fig-836 Cell Metabolism 33, 833–844, April 6, 2021ures 3B and 3C), and this was paralleled by an acute decrease of
blood glucose in all treatment groups within the first 3 h, persist-
ing for 24 h in mice treated with 6 nmol fatty acyl-GIP (Figures 3D
and 3E). No difference was observed in plasma levels of insulin,
c-peptide, triglycerides, or free fatty acids (Figures 3F–3I).
Consistent with the lower body weight and food intake (Figures
3A and 3B), and with recent reports demonstrating that GIPR
is present in key hypothalamic feeding centers (Adriaenssens
et al., 2019), we saw a dose-dependent increase in cFOS
neuronal activity in the ARC (Figures 3J and 3K) as well as in
nuclei of the DMH, ventromedial hypothalamus (VMH), and
lateral hypothalamus (LH), following administration of acyl-GIP
(Figures S4A–S4F). Collectively, these data show that centrally
administered fatty acyl-GIP acutely reduces body weight, food
intake, and glycemia in DIO mice, and that this correlated with
increased neuronal activation (cFOS) in key feeding centers of
the hypothalamus. These data reveal that pharmacological acti-
vation of CNS-GIPR signaling is relevant for energy metabolism.
Chronic central administration of fatty acyl-GIP reduced
body weight, food intake, and glycemia in HFD-fed WT
mice, but not in CNS-Gipr KO mice
We next continuously infused fatty acyl-GIP centrally (i.c.v.) at
doses of either 0.02 or 0.04 nmol/day for 12 days in DIO mice
and compared its metabolic effects to mice that were pair-fed
to match the food intake of the fatty acyl-GIP (0.04 nmol/day)-
treated mice as well as to mice treated with liraglutide
(0.04 nmol/day). Both acyl-GIP-treated groups show greater
body weight loss relative to mice treated with vehicle or liraglu-
tide (Figure 4A). After 6 days of treatment, mice treated with fatty
acyl-GIP (0.04 nmol/day) exhibit greater weight loss relative to
the pair-fed controls (Figure 4A). Consistent with the ability of
fatty acyl-GIP to decrease body weight, we saw fat mass and
food intake decreased (Figures 4B and 4C), but this was not par-
alleled by transcriptional changes in hypothalamic Npy, Agrp,
Pomc, or Cart (Figure S5A). These data thus indicate that
most, but not all, of the body weight-lowering effect of centrally
administered fatty acyl-GIP is mediated by inhibition of food
intake. Fasting levels of blood glucose were decreased in all
treatment groups, but with the greatest improvement in mice
treated with the highest dose of fatty acyl-GIP (Figure 4D). Simi-
larly, mice treated with the highest dose of fatty acyl-GIP showed
lower fasting levels of insulin and leptin (Figures 4E and 4F) and
improved insulin sensitivity relative to the vehicle controls (Fig-
ure 4G). Fatty acyl-GIP-mediated lowering of body weight and
glycemia was not related to transcriptional changes of Gipr in
the hypothalamus or the adipose tissue (Figure 4H). No differ-
ence was observed in plasma levels of triglycerides or choles-
terol (Figures S5B and S5C), but consistent with the decreased
body weight, mice treated with acyl-GIP at both dose levels
showed decreased adipocyte size in the iWAT and reduced hep-
atostatosis (Figures S5D and S5E).
To further interrogate the role of central Gipr agonism on en-
ergy metabolism, we chronically (i.c.v.) infused fatty acyl-GIP
at a dose of 0.02 nmol/day in HFD-fed WT and CNS-Gipr KO
mice. Consistent with previous data, body weight, food intake,
and blood glucose were decreased in WTmice treated with fatty
acyl-GIP, but centrally administered acyl-GIP failed to improve
body weight, food intake, or blood glucose in CNS-Gipr KO
Figure 2. Humanized (h)GIPR knockin mice with conditional CNS-specific hGIPR deletion are protected from diet-induced obesity and
glucose intolerance
(A–D) Body weight (A), body composition (B and C), and food intake (D) in male C57BL/6N WT and CNS-hGIPR KO mice (N = 6–8 mice each group).
(E) Hypothalamic expression of proopiomelanocortin (Pomc), brain-derived neurotrophic factor (Bdnf), cocaine-and-amphetamine-regulated transcript (Cart),
agouti-related peptide (Agrp), and neuropeptide y (Npy) in 20-week-old male mice (N = 6–7 mice each group).
(F and G) Energy expenditure (F) and locomotor activity (G) in 20-week-old male mice (N = 6 mice each group).
(H–P) Intraperitoneal glucose tolerance (H) and fasting levels of blood glucose (I), insulin (J), GLP-1 (K), leptin (L), triglycerides (M), free fatty acids (N), GIP (O), and
cholesterol (P) in WT and CNS-hGIPR KO mice (N = 6–8 mice each group).
(Q) H&E staining of hepatic lipid accumulation (scale bar represents 100 mm).
Data represent means ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001. Longitudinal data (A and H) were analyzed using two-way ANOVAwith time and genotype as
co-variables and Bonferroni post hoc analysis for individual time points. Bar graphs (B–E and G–P) were analyzed using two-tailed, two-sided t test. Data in (F)
were analyzed using ANCOVA with body weight as co-variate.
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fatty acyl-GIP to lower body weight, food intake, and glycemia
requires the CNS GIPR.
Peripheral administration of fatty acyl-GIP reduces body
weight through inhibition of food intake without
affecting energy expenditure
We next assessed the metabolic effects of peripherally injected
fatty acyl-GIP in DIO mice. Chronic peripheral (s.c.) administra-
tion of acyl-GIP decreased body weight in DIO mice (Figure 5A),
and this was paralleled by both acute and sustained inhibition of
food intake (Figures 5B and 5C) with a greater preference for
smaller meals without difference in meal frequency (Figures 5D
and 5E). Consistent with the inhibition of food intake, GIP treat-
ment acutely increased fatty acid oxidation (Figure 5F), and
this correlated with enhanced lipid utilization, as indicated by a
lower respiratory exchange ratio (RER) (Figure 5G). Peripheral
administration of acyl-GIP neither acutely nor chronically
affected energy expenditure (Figures 5H and 5I) or genes related
to thermogenesis in BAT (Figure S6A). Consistent with this, we
saw no effect of GIP on oxygen consumption in cultured brownadipocytes (Figure S6B). Interestingly, however, acyl-GIP
decreased assimilated energy and assimilation efficiency (Fig-
ures 5J and 5K), indicating that peripheral delivery of GIP, apart
from decreasing food intake, also decreases the amount of
metabolizable energy. In line with our data showing that central
administration of acyl-GIP increased cFOS neuronal activity in
key hypothalamic feeding centers (Figures 3J, 3K, and S4A–
S4F), we also saw cFOS increased in the ARC and the VMH after
peripheral GIP treatment (Figures 5L–5N). Consistent with the
observation that centrally administered acyl-GIP does not
change expression of Npy or Pomc (Figure S5A), we saw no dif-
ferences in c-FOS/NPY co-localization after peripheral acyl-GIP
administration relative to vehicle-treated controls (Figure 5O).
Collectively, these data demonstrate that peripheral administra-
tion of acyl-GIP decreased body weight through inhibition of
food intake, enhanced fatty acid oxidation, and decreased
metabolizable energy, without affecting energy expenditure or
BAT function. The observation that inhibition of food intake after
administration of acyl-GIP correlates with increased c-FOS in the
hypothalamic ARC and VMH suggests that GIP regulation of
food intake is centrally regulated.Cell Metabolism 33, 833–844, April 6, 2021 837
Figure 3. Acute central administration of acyl-GIP improves body weight, food intake, and glycemia in DIO mice
(A–E) Body weight change (A), food intake (B and C), and plasma levels of blood glucose (D and E) in male DIOmice treated centrally (i.c.v.) with a single dose of 1,
3, or 6 nmol acyl-GIP (N = 7–8 mice each genotype).
(F–I) Ad libitum plasma levels of insulin (F) and c-peptide (G) and plasma levels of triglycerides (H) and free fatty acids (I) in 32-week-old DIO mice (N = 6–8
each group).
(J and K) cFOS immunofluorescence (J) and cFOS quantification (N = 6–7mice each genotype) (K) in the hypothalamic arcuate nucleus (ARC) of DIOmice treated
with acyl-GIP.
Data representmeans ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001. Scale bar, 100 mm. Longitudinal data (A, B, and D) were analyzed using two-way ANOVAwith
time and genotype as co-variables and Bonferroni post hoc analysis for individual time points. Bar graphs in (C), (E)–(I), and (K) were analyzed using one-
way ANOVA.
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reduced body weight, food intake, and glycemia via
CNS-GIPR signaling
We next assessed whether the metabolic effects of peripherally
administered fatty acyl-GIP (Figure S1G) depend on CNS-GIPR
signaling. While chronic daily s.c. treatment with fatty acyl-GIP
(100 nmol/kg/day) decreased body weight in DIO WT mice,
this effect was blunted in the CNS-Gipr KO mice (Figures 6A
and 6B). Interestingly, while the body weight-lowering effect of
peripherally administered fatty acyl-GIP is blunted, but not
completely absent, in CNS-Gipr KO mice, we saw no effect of
fatty acyl-GIP on food intake in CNS-Gipr KO mice (Figures 6C
and 6D), implicating non-food-intake-related mechanisms inde-
pendent of CNS Gipr signaling that contribute to GIPR agonism-
mediated body weight lowering. These data are thus consistent
with our observation that peripherally applied GIP not only de-
creases food intake, but also decreases metabolizable energy
(Figures 5J and 5K). Importantly, fatty acyl-GIP completely loses
its effects on body weight and food intake in global germlineGipr838 Cell Metabolism 33, 833–844, April 6, 2021KOmice (Figures 6E–6H), but shows preserved effects on reduc-
tion of body weight and food intake in GLP-1R KOmice (Figures
6I–6L). These data suggest that the CNS-GIPR independent
weight-lowering effect of fatty acyl-GIP, i.e., the decrease in
metabolizable energy, may be mediated via peripheral GIPR
signaling, independent of GLP-1R signaling.
We also evaluated whether CNS-GIPR signaling contributed
to the metabolic benefits of a unimolecular fatty acylated GLP-
1/GIP dual-agonist (Finan et al., 2013). Daily peripheral (s.c.)
treatment of DIO mice with fatty acyl-GLP-1/GIP (MAR709,
10 nmol/kg/day) for 12 days decreased body weight with supe-
rior efficacy relative to a pharmacokinetically matched (IUB1746;
Figure S1G) fatty acyl-GLP-1 mono-agonist (p < 0.0001; Fig-
ure 7A). The greater body weight loss in mice treated with the
dual-agonist was accompanied by a greater decrease in body
fat mass (Figure 7B) without difference in lean tissue mass (Fig-
ure 7C) and a greater decrease in food intake and improved
glucose tolerance relative to treatment with fatty acyl-GLP-1
alone (Figures 7D–7F). While GLP-1 fully retained its ability to
Figure 4. Chronic central administration of acyl-GIP improves body weight, food intake, and glycemia in HFD-fed WT mice, but not in CNS-
Gipr KO mice
(A–C) Body weight (A), eWAT weight (B), and food intake (C) of HFD-fed mice treated with acyl-GIP (0.02 or 0.04 nmol/day) or liraglutide (0.04 nmol/day) or that
were pair-fed to the acyl-GIP (0.04 nmol/day)-treated mice (N = 9–10 each group).
(D–G) Fasting plasma levels of blood glucose (D), insulin (E), leptin (F), and HOMA-IR (G) after 14 days of treatment (N = 7–10 mice each group).
(H) Expression of Gipr in iWAT, eWAT, and hypothalamus after 14 days of treatment (N = 7–10 mice each group).
(I–K) Body weight change (I), food intake (J), and fasting blood glucose (K) in HFD-fed WT and CNS-Gipr KOmice following treatment with 0.02 nmol/day of acyl-
GIP (N = 9–10 mice each genotype).
Data represent means ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001. Longitudinal data (A, C, I, and J) were analyzed using two-way ANOVA with time and
genotype as co-variables and Bonferroni post hoc analysis for individual time points. Bar graphs in (B), (D)–(H), and (K) were analyzed using one-way ANOVA.
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KO mice, the GLP-1/GIP dual-agonist lost its superior potency
over GLP-1 (Figures 7A–7F). Of note, the GLP-1/GIP dual-
agonist also equally improved glucose tolerance in WT and
CNS-Gipr KO mice (Figures 7E and 7F), which is consistent
with the shown preservation of islet Gipr expression (Figure 1U)
and the demonstration of fully preserved insulinotropic action of
GIP andGLP-1 in the islets of theCNS-GiprKOmice (Figure 1W).
Together, these data show that the GLP-1/GIP dual-agonist im-
proves body weight and food intake via the CNS GIPR and im-
proves glucose handling via peripheral mechanisms. Notably,these data further demonstrate that the CNS-Gipr KO mice do
not show alterations in the responsiveness to GLP-1 treatment.
DISCUSSION
Here we report that body weight and glucose control are
improved in HFD-fed mice with CNS deletion of either mGipr
or hGIPR and that central loss of Gipr coincides with decreased
food intake without alterations in energy expenditure. The obser-
vation that CNS-Gipr KO mice are protected from diet-induced
obesity is consistent with the phenotype seen in global germlineCell Metabolism 33, 833–844, April 6, 2021 839
Figure 5. Peripheral administration of acyl-GIP decreases food intake and activates cFOS in the hypothalamic ARC and VMH in DIO mice
(A–C) Body weight (A) and acute (B) and chronic (C) effects of peripherally (s.c.) administered acyl-GIP (30 nmol/kg/day) on food intake in 21-week-old male DIO
mice (N = 8 mice each group).
(D–I) Meal size (D) and frequency (E), acute acyl-GIP effects on fatty acid oxidation (F), respiratory exchange ratio (RER) (G), and acute and chronic effects of acyl-
GIP on energy expenditure (H and I) in 21-week-old male DIO mice (N = 8 mice each group).
(J and K) Assimilated energy (J) and assimilation efficiency (K) in mice chronically treated daily s.c. for 7 days with acyl-GIP (N = 8 mice each group).
(L–O) Staining and quantification of cFOS in the ARC (L), DMH (M), and VMH (N) and cFOS/NPY co-staining (O) in the ARC of 19-week-old male HFD-fed NPY-
GFP mice treated with a single peripheral (s.c.) injection of either vehicle or acyl-GIP (30 nmol/kg) (N = 5 mice each group; scale bar, 100 mm).
Data represent means ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001. Longitudinal data (A–C, F, and H) were analyzed using two-way ANOVA with time and
genotype as co-variables and Bonferroni post hoc analysis for individual time points. Bar graphs in (E), (G), and (J)–(O) were analyzed using two-tailed, two-sided t
test. Data in (I) was analyzed using ANCOVA with body weight as co-variate.
ll
OPEN ACCESS ArticleGipr KO mice (Miyawaki et al., 2002) and suggests that central
GIPR signaling plays a relevant role in regulating energy meta-
bolism. It would be interesting to assess in future studies
whether ablation of Gipr later in life leads to a metabolic pheno-
type comparable to what has been reported using pharmacolog-
ical inhibition of GIPR. It would be interesting to assess whether
the point in timewhenGipr is ablated affects the susceptibility for
body weight gain later in life. An epigenetic influence on the sus-
ceptibility to diet-induced obesity and insulin resistance has pre-
viously been shown for C57BL/6N mice (Huypens et al., 2016).
Nonetheless, there remains great uncertainty as to whether
GIPR activity should be activated or inhibited for the treatment
of obesity and T2DM. This confusion stems from experimental
evidence demonstrating that both GIPR agonists and antago-840 Cell Metabolism 33, 833–844, April 6, 2021nists improve body weight and glucose control in animal models
of obesity. Unimolecular GLP-1/GIP dual-agonists lead, relative
to GLP-1 alone, to greater improvement of body weight and
glucose control in obese animals and humans (Coskun et al.,
2018; Finan et al., 2013; Frias et al., 2018). In this regard, it has
been hypothesized that the GIP entity of the GLP-1/GIP dual-ag-
onists might accelerate GLP-1 receptor signaling (Holst and
Rosenkilde, 2020). But notably, our data show that GLP-1/GIP
loses its superior potency over GLP-1 in CNS-Gipr KO mice,
and while GIP still lowers body weight and food intake in GLP-
1R KO mice, it fails to affect body weight and food intake in
global Gipr KO mice. These data collectively argue that GLP-1/
GIP improves body weight and food intake via CNS GIPR
signaling.
Figure 6. Chronic peripheral administration of acyl-GIP improves body weight, food intake, and glycemia via CNS-GIPR signaling
(A–D) Body weight change (A), placebo-corrected total body weight loss (B), and food intake (C and D) of HFD-fed WT and CNS-Gipr KO mice treated with
100 nmol/kg/day of acyl-GIP (N = 8 mice each group).
(E–H) Body weight change (E), placebo-corrected total body weight loss (F), and food intake (G and H) of HFD-fed WT and global Gipr KO mice treated with
100 nmol/kg/day of acyl-GIP (N = 12–13 mice each group).
(I–L) Body weight change (I), placebo-corrected total body weight loss (J), and food intake (K and L) of HFD-fed WT and global GLP-1R KO mice treated with
100 nmol/kg/day of acyl-GIP (N = 6–8 mice each group).
Data represent means ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001. Longitudinal data (A, C–E, G–I, K, and L) were analyzed using two-way ANOVAwith time and
genotype as co-variables and Bonferroni post hoc analysis for individual time points. Bar graphs in (B), (F), and (J) were analyzed using one-way ANOVA.
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potentially underly the seemingly conflicting observation that
GIPR activation also decreases body weight. It has been sug-
gested that GIPR agonists might lower body weight through
decreasing Gipr expression and hence through functional
GIPR antagonism (Holst and Rosenkilde, 2020). Arguing
against this hypothesis, we show in our manuscript that chronic
central administration of acyl-GIP lowers body weight and food
intake in DIO mice without changes in Gipr expression in the
hypothalamus, eWAT, or iWAT. Furthermore, we show that sin-
gle central administration of acyl-GIP is sufficient to lower body
weight and food intake and to acutely induce neuronal activa-
tion (cFOS) in key hypothalamic feeding centers. These data
collectively indicate that the ability of acyl-GIP to decrease
body weight and food intake is mediated via CNS GIPR
signaling and is unlikely driven by functional GIPR antagonism.
Relevant hypotheses may further include observations that
antagonizing GIPR signaling enhances the anorectic effect of
leptin (Kaneko et al., 2019) and that GIPR antagonism improves
WAT blood flow and nutrient supply (Asmar et al., 2017;
Samms et al., 2020). Hence, it is possible that the body
weight-lowering effect of GIPR antagonism resides in periph-
eral mechanisms on the adipose tissue while central GIPR ag-onism decreases body weight through centrally mediated inhi-
bition of food intake. In line with this notion, we show that single
central (i.c.v.) administration of fatty acyl-GIP improves body
weight and glycemia in DIO mice and that this coincides with
decreased food intake and acute neural activation (measured
as cFOS) in key feeding centers of the hypothalamus, including
the ARC, DMH, VMH, and LH. Similar hypothalamic cFOS pat-
terns are also observed upon acute peripheral administration of
acyl-GIP. These data hence indicate that CNS GIPR plays a
direct relevant role in regulating systemic energy metabolism
in mice, and pharmacologically activating this receptor de-
creases food intake and body weight. The data are consistent
with previous findings showing presence of Gipr in these hypo-
thalamic areas (Adriaenssens et al., 2019) and indicate that
these acute effects of GIPR agonism are centrally mediated
and unlikely driven by receptor desensitization or functional
antagonism. Consistent with a relevant role of CNS GIPR
signaling, chronic central administration of acyl-GIP decreases
body weight and food intake, and improves glycemia in DIO WT
mice with no effect of acyl-GIP on body weight, food intake, or
glycemia in CNS-Gipr KO mice. These data thus confirm that
centrally administered acyl-GIP decreases body weight and
food intake via the CNS GIP receptor.Cell Metabolism 33, 833–844, April 6, 2021 841
Figure 7. GLP-1/GIP loses superior potency over GLP-1 upon chronic peripheral treatment in CNS-Gipr KO mice
(A–D) Change in body weight (A), fat mass (B), lean mass (C), and food intake (D) of HFD-fed WT and CNS-Gipr KO mice treated with acyl-GLP-1 or GLP-1/GIP
(MAR709) at a dose of 10 nmol/kg/day (N = 7–8 mice each group).
(E and F) Intraperitoneal glucose tolerance after 12 days of treatment (N = 7–8 mice each group).
Data represent means ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001. Longitudinal data (A and E) were analyzed using two-way ANOVAwith time and genotype as
co-variables and Bonferroni post hoc analysis for individual time points. Bar graphs in (B)–(D) and (F) were analyzed using one-way ANOVA.
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treatment and do not show alterations in Gipr expression in the
pancreatic islets. Consistent with this, both incretin hormones
show preserved ability to stimulate islet insulin secretion in
CNS-Gipr KO mice. Improvement of systems metabolism by
centrally administered acyl-GIP is also not related to Gipr down-
regulation in the hypothalamus or the adipose tissue, again sug-
gesting that improvement of systems metabolism by acyl-GIP is
not related to reduced GIPR activity. Interestingly, while centrally
administered acyl-GIP fails to affect body weight and food intake
in CNS-Gipr KOmice, peripherally administered acyl-GIP shows
blunted, but not completely absent, weight lowering efficacy in
CNS-Gipr KO mice. Consistent with this, we see both reduction
of food intake and assimilation efficiency following peripheral
acyl-GIP treatment in DIO mice. The latter might be associated
with the ability of GIP to inhibit gastric motility. While these
data indicate that acyl-GIP lowers body weight via CNS GIPR-
dependent and -independent mechanisms, we see no effect of
peripherally administered acyl-GIP on food intake in the CNS-
Gipr KO mice. Thus, acyl-GIP decreases body weight via CNS-
GIPR-mediated regulation of food intake and beyond this via
mechanisms not related to food intake that are independent of
CNS GIPR. These data are also in line with the greater decease
in body weight of acyl-GIP-treated mice relative to pair-fed con-
trols. Nonetheless, acyl-GIP shows no effect on body weight,
food intake, or glycemia in global Gipr KO mice, but preserved
effects in GLP-1R KO mice. The non-CNS-GIPR effects of
acyl-GIP on body weight are thus mediated via peripheral
GIPR signaling and unrelated to GLP-1R signaling. Potential842 Cell Metabolism 33, 833–844, April 6, 2021beneficial GIP effects mediated by peripheral GIPR agonism
also include the increase of lipid buffering in the WAT to protect
from metabolic derangements that might result from lipid spill-
over and ectopic lipid deposition in peripheral tissues (Samms
et al., 2020). Of note, the GLP-1/GIP dual-agonist (MAR709)
loses its superior efficacy on body weight and food intake over
GLP-1 in the CNS-Gipr KO mice, thus indicating that this dual-
agonist acts in part via the CNS-GIPR to improve systems meta-
bolism. These data hence further argue that the dual-agonist
does not improve metabolism exclusively by enhanced GLP-
1R signaling. In summary, our data establish that CNS Gipr
signaling is of essential relevance for systemic energy meta-
bolism control and for the metabolic efficacy of GIP-based
pharmacotherapies.
Limitations of study
We report the metabolic phenotype of mice in which GIPR has
been deleted using mice that express the cre recombinase under
control of the nestin promoter. While our data show selective
reduction of Gipr expression in the hypothalamus, but not in iso-
lated islets, bonemarrow, orWAT and BAT, it is known that nestin
can also to some extent be expressed external to the CNS (Harno
et al., 2013). While our data clearly demonstrate that CNS GIPR
signaling plays an important role in the regulation of energy meta-
bolism, we can (like in many other cre models) not fully exclude a
certain degree of off-target excision in certain cells/tissues
external to the CNS. We notably see only borderline detectable
expression of Gipr in the WAT and BAT. While this is consistent
with previous studies (Adriaenssens et al., 2019), mechanistic
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OPEN ACCESSArticleattribution of findings to tissues expressing low levels of receptor
expression should be done with caution. Also, the lack of suffi-
ciently sensitive and specific antibodies to quantify GIPR protein
is a limitation of the study. Notably, nestin cre mice are reported
in some studies to have lower leanmass and reduced body length
(Harno et al., 2013). In our studies we therefore used nestin cre+/
mGiprwt/wt mice as controls for the nestin cre+/ mGiprflx/flx mice.
For the studies using the nestin cre+/ hGIPRflx/flx mice, we
confirmed that nestin cre/ hGiprflx/flx mice do not differ in either
body weight or blood glucose from nestin cre+/ hGiprwt/wt and
nestin cre/ hGiprwt/wt mice. Finally, it has to be noted that we
used for our studies a fatty acid acylated GIP (Figure S1D), which
despite being mechanistically comparable to native GIP (Mroz
et al., 2019), potentially differs from the native peptide in both
the in vivo potency and pharmacokinetics.STAR+METHODS
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S., Hrabe de Angelis, M., and Beckers, J. (2016). Epigenetic germline inheri-
tance of diet-induced obesity and insulin resistance. Nat. Genet. 48, 497–499.
Kaneko, K., Fu, Y., Lin, H.Y., Cordonier, E.L., Mo, Q., Gao, Y., Yao, T., Naylor,
J., Howard, V., Saito, K., et al. (2019). Gut-derived GIP activates central Rap1
to impair neural leptin sensitivity during overnutrition. J. Clin. Invest. 129,
3786–3791.844 Cell Metabolism 33, 833–844, April 6, 2021Killion, E.A., Wang, J., Yie, J., Shi, S.D., Bates, D., Min, X., Komorowski, R.,
Hager, T., Deng, L., Atangan, L., et al. (2018). Anti-obesity effects of GIPR an-
tagonists alone and in combination with GLP-1R agonists in preclinical
models. Sci. Transl. Med. 10, eaat3392.
Kim, S.J., Nian, C., and McIntosh, C.H. (2007). Activation of lipoprotein lipase
by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a
protein kinase B, LKB1, and AMP-activated protein kinase cascade. J. Biol.
Chem. 282, 8557–8567.
Kim, S.J., Nian, C., andMcIntosh, C.H. (2010). GIP increases human adipocyte
LPL expression through CREB and TORC2-mediated trans-activation of the
LPL gene. J. Lipid Res. 51, 3145–3157.
Kim, S.J., Nian, C., Karunakaran, S., Clee, S.M., Isales, C.M., and McIntosh,
C.H. (2012). GIP-overexpressing mice demonstrate reduced diet-induced
obesity and steatosis, and improved glucose homeostasis. PLoS One 7,
e40156.
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H.,
Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002). Inhibition of gastric
inhibitory polypeptide signaling prevents obesity. Nat. Med. 8, 738–742.
Mroz, P.A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M.H., DiMarchi, R.D.,
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Antibodies
Rabbit polyclonal anti-cFos Synaptic System Cat# 226003;RRID: AB_2231974
Alexa Fluor 568 donkey-anti-rabbit Thermo Fisher Scientific Cat# A10042;RRID: AB_2534017
Chemicals, Peptides, and Recombinant Proteins
acyl-GIP Mroz et al., 2019 IUB0271
acyl-GLP-1 Mroz et al., 2019 IUB1746
GLP-1/GIP Mroz et al., 2019 MAR709
Liraglutide Finan et al., 2013 Novo Nordisk
Hematoxylin and Eosin (H&E) Sigma-Aldrich Cat# 517-28-2
Metamizol HMGU Internal Pharmacy N/A
Ketamine HMGU Internal Pharmacy N/A
Xylazine HMGU Internal Pharmacy N/A
Meloxicam HMGU Internal Pharmacy N/A
collagenase P Sigma-Aldrich Cat# 11213865001
Hanks Balanced Salt Solution (HBSS) Thermo Fisher Scientific Cat# 14065056
RPMI medium 1640 Sigma Cat# R8758
Paraformaldehyde (PFA) Sigma Cat# 158127
Dexamethasone Sigma Cat# D1756
IBMX Sigma Cat# 15879
Indomethacine Sigma Cat# I7378
Rosiglitazone VWR Cat# CAYM71740-10
T3 Sigma Cat# T6397
Insulin Sigma Cat# I9278
Oligomycin Sigma Cat# O4876
Dinitrophenol Sigma Cat# 34334
Rotenone Sigma Cat# R8875
Isoproterenol Sigma Cat# I6504
Antimycin A Sigma Cat# A8674
Critical Commercial Assays
RNase Kit QIAGEN Cat# 74106
QuantiTect reverse transcription kit QIAGEN Cat# 205313
SYBR Green qPCR Master Mixes Thermo Fisher Scientific Cat# 4364344
Ultrasensitive mouse insulin ELISA kit Crystal Chem Cat# 90080
Mouse C-Peptide ELISA kit Crystal Chem Cat# 90050
Mouse total GLP-1 ELISA kit Crystal Chem Cat# 81508
Mouse leptin ELISA kit Crystal Chem Cat# 90030
Triglyceride assay kit Cobas Roche/Hitachi Cat# 11489232
Triglyceride assay kit Wako Chemical Cat# 290-63701
Total cholesterol assay kit Cobas Roche/Hitachi Cat# 11877771
Total cholesterol assay kit Wako Chemical Cat# 993-02501
NEFA-HR(2) Assay Wako Chemical Cat# 91797&91898
Pierce BCA Protein assay Kit Thermo Fisher Scientific Cat# 23225
HbA1c kit Axonlab Cat#10698915
96-well Genomic DNA Kit Favorgen Cat# FADWE 96004
Alzet brain infusion kit 3 Alzet Cat# 0008851
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REAGENT or RESOURCE SOURCE IDENTIFIER
Alzet osmotic minipump (Alzet model 1002 Alzet Cat# 0004317
Experimental Models: Organisms/Strains
BAT primary cells harvested from naive
C57BL6/J mice
This paper N/A
Experimental Models: Cell Lines
B6.Cg-Tg(Nes-cre)1Kln/J The Jackson Laboratory Cat#003771
C57BL/6J(Giprflx/flx) Campbell et al., 2016 N/A
C57BL/6N(GIPRflx/flx) This paper Boehringer Ingelheim
Oligonucleotides
Primers for RT PCR, see Table S1 This paper N/A
Software and Algorithms
GraphPad Prism 8.0 GraphPad N/A
GraphPad Prism 9.0 GraphPad N/A
ImageJ NIH Image N/A
SPPS v. 26 IBM N/A
Other
TSE Phenomaster TSE Systems N/A
ll
OPEN ACCESS ArticleRESOURCE AVAILABILITY
Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Timo D.
M€uller (timo.mueller@helmholtz-muenchen.de).
Materials Availability
This study did not generate new unique reagents. The drugs used in this study were kindly provided by Novo Nordisk Research Cen-
ter Indianapolis. Nestin cre mice are available from the Jackson Laboratories (Stock No. 003771).
Data and Code Availability
The study did not generate/analyze datasets/codes. The raw data underlying the figure panels are available from the Lead Contact
upon reasonable request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals and housing conditions
Animal experiments were performed in accordance with the Animal Protection Law of the European Union, Switzerland or the United
States of America and upon permission by the state of Bavaria, Germany, the cantonal Veterinary Office Zurich, Switzerland, or the
University of Cincinnati, OH, USA.
Only naive male mice were used in the studies since female mice are largely protected from diet-induced obesity and glucose
intolerance.
CNS-hGIPR KO mice were provided by Boehringer Ingelheim and kept on a C57/BL6N background. CNS-hGIPR KO mice were
generated by replacing mouse Gipr (mGipr) from exon 3-14 with the human hGIPR sequence (Taconic Biosciences GmbH, Co-
logne, Germany). CNS-specific hGIPR KO mice were generated by crossing hGIPRflx/flx mice with mice expressing the cre recom-
binase under control of the nestin promoter. Nes-cre+/ hGIPRflx/flx (CNS-hGIPR KO) and littermate Nes-cre/ hGIPRflx/flx (WT)
were considered for the experiments after confirmation that Nes-cre/ hGIPRflx/flx mice do not differ in body weight or fasting
blood glucose from Nes-cre+/ hGIPRwt/wt mice (Figures S3C and S3D). Only naive male mice were considered for the experi-
ments. Mice were double-housed or single housed when aggressive behavior required separation. For metabolic phenotyping,
naive age-matched male mice were grouped based on their genotypes. Intraperitoneal glucose tolerance test (ipGTT) was as-
sessed in 18-week-old CNS-hGIPR KO mice after 6 h fasting with stimulation of 2 g glucose per kg body weight. Body compo-
sition (fat and lean mass) was assessed in 19-week-old CNS-hGIPR KO mice by Aloka LaTheta computed tomography (CT) scan-
ner using LaTheta software (Zinsser Analytic, UK). The ages and sample sizes corresponding to the individual measures are
indicated in the figure legends.e2 Cell Metabolism 33, 833–844.e1–e5, April 6, 2021
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for > 10 generations. CNS-mGipr KO mice were bred on a C57BL/6J background and were generated by crossing Giprflx/flx mice
(Campbell et al., 2016) with mice expressing the Cre recombinase under control of the nestin promoter. Giprflx/flx mice were
cross-bred for > 5 generations to C57BL/6J. Only naive male Nes-cre+/ Giprflx/flx (CNS-mGipr KO) and Nes-cre+/ Giprwt/wt mice
(WT) were considered for the study. Micewere double-housed or single housed if aggressive behavior required separation. Formeta-
bolic phenotyping (Figure 1), age-matched male mice were grouped based on their genotypes. ipGTT was assessed in 42-week-old
CNS-mGipr KOmice after 6 h fasting with stimulation of 1.75 g glucose per kg body weight. Body composition was analyzed using a
magnetic resonance whole-body composition analyzer (EchoMRI, Houston, TX). The ages and sample sizes corresponding to the
individual measures are indicated in the figure legends.
For studies using regular naive diet-induced obese (DIO) mice, C57BL/6J mice were purchased from Janvier Labs (Le Genest-
Saint-Isle, France). Mice were randomly assigned into treatment groups matched for body weight and body composition (fat and
lean tissue mass). The ages and sample sizes corresponding to the individual measures are indicated in the figure legends.
Mice were kept at a constant environment with ambient temperature set to 22 ± 2Cwith constant humidity (45 – 65%) and a 12 h/
12 h light/dark cycle. For studies inmGipr KO mice and regular DIO mice, animals had free access to water and were fed ad libitum
with either a standard chow (Type 1314, Altromin GmbH, Lage, Germany) or HFD (58% kcal fat; Research Diets, New Brunswick, NJ,
USA; cat. no. D12331). For studies using hGIPR KOmice, animals had free access to water and were fed with either a standard chow
diet (cat. no. 2222; Kliba-Nafag, Kaiseraugst, Switzerland) or a HFD (cat. no. 2127; Kliba-Nafag, Kliba-Nafag, Kaiseraugst,
Switzerland). During the experiments, the health status of the animals was checked and scored daily and included assessment of
overall behavior, skin/fur irritations, wounds and injuries, scratching behavior, piloerection or other signs of abnormal appearance.
For analysis of mitochondrial bioenergetics using seahorse technology, murine brown preadipocytes (immortalized by SV40 large T-
antigen) were harvested from8-12week-oldmale chow-fedC57BL/6Jmice purchased from the Jackson Laboratory (Cat. no. 000664).
METHOD DETAILS
For animal studies, sample sizes were calculated based on a power analysis assuming that a R 5 g difference in body weight be-
tween genotypes can be assessed with a power ofR 75% when using a 2-sided statistical test under the assumption of a standard
deviation of 3.5 and an alpha level of 0.05. Investigators were not blinded to genotypes and treatment conditions since all investiga-
tors need to be able at any time to show federal animal protocol approval, study designs, results, treatments as well as number and
genotypes of used animals to federal authorities upon spontaneous inspections by the governmental authorities. No data were
excluded from the studies unless a significant outlier was detected using a statistical outlier test (Grubbs Test; GraphPad Prizm).
No animals were excluded from the studies unless health issues demanded exclusion of single mice (e.g., due to fighting injuries,
dermatitis or due to detached brain cannulas).
Indirect calorimetry
Energy expenditure, substrate utilization (respiratory exchange ratio, RER) and home-cage activity were assessed in temporally sin-
gle-house mice using a climate-controlled indirect calorimetric system (TSE System, Bad Homburg, Germany). After acclimatization
for 24 h, levels of O2 and CO2weremeasured every 10min for 4 - 5 days. Indirect calorimetry was performed in HFD-fed 20-week-old
CNS-hGIPR KO mice and 29-week-old CNS-mGipr KO mice. Data for energy expenditure were analyzed using ANCOVA with body
weight as covariate as previously suggested (Speakman et al., 2013; Tschöp et al., 2011). Fatty acid oxidation (kcal/h) was assessed
by the formula ‘‘energy expenditure (kcal/h) x (1-RER)/0.3.’’
Bomb calorimetry
Assimilated energy and assimilation efficiency was assessed using the C200 Oxygen Bomb Calorimeter (IKA, Staufen, Germany).
Food consumption and feces production were measured/collected over 7 days during continuous daily peripheral (s.c.) acyl-GIP
treatment. Feces and foodwere dried for several days at 65 Cbefore measuring food/fecal energy content for assessment of assim-
ilated energy (KJ/g food).
Preparation of RNA and gene expression analysis
Total RNA was prepared using RNeasy Kit (QIAGEN, Hilden, Germany) according to manufacturer’s instructions. cDNA synthesis
was performed using QuantiTect Reverse Transcription Kit (QIAGEN, Hilden, Germany) according to manufacturer’s instructions.
Gene expression was profiled using quantitative PCR-based (qPCR) techniques using SYBR green or TaqMan Single Probes
(Thermo Fisher Scientific, Erlangen, Germany). The relative expression of the selected genes was measured using the 7900HT
Fast Real-Time PCRSystem (Thermo Fisher Scientific, Erlangen, Germany). The relative expression levels of each gene were normal-
ized to the housekeeping gene peptidylprolyl isomerase B (Ppib), Hypoxanthine Phosphoribosyltransferase (Hprt), or Acidic ribo-
somal phosphoprotein P0 (36B4). For primer sequences see Table S1.
Intracerebroventricular (icv) drug treatment
Mice received one oral drop of Metamizol (appx. 50 ml) and were subsequently anaesthetized using ketamine (7 mg/kg) /xylazine
(100 mg/kg). Mice were then treated with Lidocaine (6 mg/kg) followed by implantation of a cannula (Alzet brain infusion kit 3,Cell Metabolism 33, 833–844.e1–e5, April 6, 2021 e3
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below skull) using a stereotaxic apparatus (David Kopf Instruments, USA). For the acute study, 1 ml of 0.9% saline and acyl-GIP were
applied to their respective experimental group. Body weight, food intake, and ad lib blood glucose were recorded as described. For
chronic drug treatment, the cannula (Alzet brain infusion kit 3, Cupertino, CA) was connected to an Alzet osmotic minipump (Alzet
model 1002, Cupertino, CA; flow rate 0.25 ml/h, delivery rate 14 days) via a 2 cm-long vinyl tubing. The minipumps were filled with
0.9% saline, acyl-GIP, or liraglutide, then primed overnight at 37C in 0.9% saline before subcutaneous implantation. After surgery,
mice received meloxicam (1 mg/kg) subcutaneously every 12 h for the first post-operative days.
Drug treatment and body composition
Mice were treated daily via subcutaneous injection in a volume of 5 ml per gram body weight. Body composition was analyzed using a
magnetic resonance whole-body composition analyzer (EchoMRI, Houston, TX). For glucose tolerance, levels of blood glucose were
sampled from 6 h fasted mice following intraperitoneal administration of 1.75 g glucose per kilogram body weight.
Meal size and feeding patterns
Meal patterns were analyzed from food intake data collected in the calorimetric chambers using a moving average of 40 min food
intake per animal. Time coherent time windows with a moving average above 0.009 g were defined as a meal. Total meal sizes
were binarized into four categories: small (< 0.09), medium (> 0.09 - 0.13), large (> 0.13 - 0.18), very large (> 0.18). Significance be-
tween meal sizes were calculated using Student’s t test. Single individual data points indicating shredding of food (R 0.25 g / 10 min)
were excluded from the analysis.
Analysis of plasma samples
Blood samples were collected and immediately kept on ice, centrifuged at 3000 g and 4C. Plasma was stored at 80C. Plasma
total immunoreactive insulin, C peptide, total GLP-1 and leptin were measured using commercially available ELISA kits from Crystal
Chem, Zaandam, Netherlands (Insulin cat. no. 90080; c-peptide cat. no. 90050, GLP-1 cat. no. 81508, Leptin cat. no. 90030). Plasma
triglycerides were determined using commercially available kits from either Roche Diagnostics International, Switzerland (cat. no.
11489232) orWakoChemical (Wako Pure Chemical Industries, Japan). Total cholesterol was determined using kits from either Roche
Diagnostics International, Switzerland (cat. no. 11877771) orWako Pure Chemical Industries, Japan (cat no. 993-02501). Plasma FFA
levels were determined using kits fromWako Pure Chemical Industries, Japan (cat. no. 9196). All ELISAs were performed according
to the manufacturer’s instruction.
Islet isolation
For islet isolation, the pancreas was perfused with 6 mg/mL of collagenase P (Sigma-Aldrich, Germany, cat. no. 11213865001) and
dissolved in Hanks Balanced Salt Solution (HBSS; Thermofisher Scientific, Planegg, Germany, cat. no. 14065056) with Ca2+/Mg2+.
After applying to a gradient solution, islets were isolated and were handpicked under the microscope. Islets were kept overnight at
37C 5% CO2 in culture with 11 mM glucose in RPMI medium 1640 (Sigma Aldrich, Taufkirchen, Germany, cat no. R8758) supple-
mented with 10% (vol/vol) FBS Heat Inactivated, 1% (vol/vol) penicillin and streptomycin (Bastidas-Ponce et al., 2019).
Glucose-stimulated insulin secretion (sGSIS)
The islets were transferred to a 96-well plate, and the culture media was replaced with Krebs-Ringer bicarbonate buffer (Sigma Al-
drich, Taufkirchen, Germany, cat. no. K4002) modified with HEPES (KRBH) containing 129 mMNaCl, 4.8 mM KCl, 1.2 mM KH2PO4,
1.2 mMMgSO4$H2O, 2 mM CaCl2, 24 mMNaHCO3, 6 mM HEPES, and 0.2% bovine serum albumin with PH adjusted to 7.4. Then,
the islets were incubated for 1 h in starving glucose media (KRBH with 1 mM Glucose) before starting the GSIS. Different glucose
concentrations (2.8 and 16.8 mM) were added to the islets (for 1 h each). For compound treatment, a concentration of 10 nM of
GLP-1 or GIP was added during the GSIS. The supernatants were collected and used for insulin measurement. Islets were lysed
for DNAmeasurements. Insulin levels were measured with the ultrasensitive insulin ELISA kit (Crystal Chem, Zaandam, Netherlands,
cat. no. 90080). The data was normalized to the DNA content.
Immunohistochemistry
For cFOS staining, HFD-fed WT or NPY-GFP mice (Pinto et al., 2004) were anesthetized with CO2 1.5 h after either central (icv) or
peripheral (s.c.) injection of the acyl-GIP, and transcardially perfused with phosphate-buffered saline (PBS) followed by 4% neutral
buffered paraformaldehyde (PFA). Brains were harvested and equilibrated in 30% sucrose for three days, and sliced on a cryostat in
the coronal plane at 30 mm. Slices were washed 5 times with 0.5%Triton X-100 in tris-buffered saline (TBS) followed by 1 h block with
SUMI (0.25%gelatin and 0.5% Triton X-100 in TBS). After blocking, slices were incubated overnight with primary antibody anti-cFOS
(Synaptic system, Goettingen, Germany; rabbit polyclonal antibody cat. no. 226003, dilution: 1:2000,) in SUMI at 4C. After 5 times
wash in TBS, slices were incubated 1 h with Alexa Fluor 568 donkey-anti-rabbit (Molecular Probes, Life Technologies GmbH, Darm-
stadt, Germany, dilution 1:1000) secondary antibody. After several washes, slices were mounted on gelatin-pre-coated glass slides,
and coverslipped for image quantification. ImageJ was applied for quantifying cFOS postivie cells and cFOS-NPY co-localized cells.
Images of single focal planes were captured at 20X magnification by a Leica SP5 scanning confocal microscope. The number ofe4 Cell Metabolism 33, 833–844.e1–e5, April 6, 2021
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performed without previous knowledge of the experimental group.
Histopathology
Mice were sacrificed by cervical dislocation. Liver and iWAT were embedded in paraffin using a vacuum infiltration processor Tis-
sueTEK VIP (Sakura), and processed as 3 or 4 mm slides using a HMS35 rotatory microtome (Zeiss) before H&E staining. For H&E
staining, rehydration was done in a decreasing ethanol series, rinsing with tap water, 2 minMayers acid Hemalum, bluing in tap water
followed by 1 min EosinY (both Sigma-Aldrich, MO, USA). Dehydration was performed in an increasing ethanol series, mounting with
Pertex (Medite GmbH, Burgdorf, Germany), and coverslips (Carl Roth Chemicals, Karlsruhe, Germany). The slides were evaluated
independently using a brightfield microscope (Axioplan; Zeiss, Jena, Germany). Steatosis was graded by the presence of fat vacu-
oles in liver cells according to the percentage of affected tissue (0: < 5%; 1: 5%–33%; 2: 33%–66%; 3: > 66%); the number of sam-
ples falling into each grade divided by total sample number was considered the percentage of steatosis grade.
Seahorse respirometry
Murine brown preadipocytes (immortalized by SV40 large T-antigen) were harvested from 8-12 week old male chow-fed C57BL/6J
mice, plated onto XF96 V3 PET cell culture microplates (Agilent Technologies; 12K per well) and individually differentiated. At con-
fluency, differentiation was started using a brown fat differentiation cocktail (growth media, 5 mM dexamethasone, 0.5 mM IBMX,
125 mM indomethacine, 1 mM rosiglitazone, 5 mg/mL insulin, 1 nM T3), followed at day 2 of differentiation by exposure to continuation
medium (growth media, 1 mM rosiglitazone, 5 mg/mL insulin, 1 nM T3), followed by differentiation medium (growth media, 1 mM ro-
siglitazone, 5 mg/mL insulin, 1 nM T3) from day 4 to 6. Before measurements of cellular respiration at day 6, the cells were washed
twice with assay medium (XF DMEM + 20mM glucose, 2 mM glutamine, 2% BSA) and then incubated in 180 mL of assay medium for
10 min without CO2 at 37C before transfer to the XF96 Extracellular Flux analyzer (Agilent Technologies). Assay cycles were set to
2minmixing and 2minmeasuring intervals. Oligomycin (5 mg/mL) served to inhibit ATP synthase, dinitrophenol (DNP; 150 mM) to fully
uncouple respiration, and a final cocktail served to correct for non-mitochondrial OCR, consisting of rotenone (5 mM) and antimycin A
(2 mM) to inhibit respiratory complexes I and III, respectively, with 2-deoxyglucose (2-DG; 100 mM).to inhibit glycolytic flux.
QUANTIFICATION AND STATISTICAL ANALYSIS
All data were analyzed using the Kolmogorov-Smirnov test for normal distribution (https://www.socscistatistics.com/tests/
kolmogorov/default.aspx). All data were normally distributed and met the assumption of the used statistical approaches. Statistical
analyses were performed using the statistical tools implemented in GraphPad Prism8 (version 8.3.0). Differences between groups
were assessed by Student’s 2-sided 2-tailed t test, 1-way ANOVA or 2-way ANOVA with time and genotype as co-variants followed
by Bonferroni’s post hoc multiple comparison testing for individual time points. The statistical tests and sample sizes underlying the
respective measures are indicated in the figure legends. All data represent means ± SEM. Asterisks indicate *p < 0.05, **p < 0.01 and
***p < 0.001. p < 0.05 was considered statistically significant. Differences in energy expenditure were calculated using ANCOVA with
body weight as co-variate using SPSS (version 24).Cell Metabolism 33, 833–844.e1–e5, April 6, 2021 e5
